Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

add-on sirolimus therapy

PreclinicalSmall molecule

RRuijin Hospital

add-on sirolimus therapy is one of 2 small molecule programs targeting Adult-Onset Still's Disease. It is currently in Preclinical.

1

Indications

1

Total Trials

1

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adult-Onset Still's DiseaseActive, not recruiting

Adult-Onset Still's DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Adult-Onset Still's Disease

#DrugCompanyPhaseTrials

Rapamune

PPrism Pharmaceuticals

add-on sirolimus therapy

RRuijin Hospital

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adult-Onset Still's Disease1 trial

Therapeutic Value of Sirolimus in Refractory Adult-Onset Still's Disease

Active, not recruiting·RRuijin Hospital·Preclinical·NCT07151157·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for add-on sirolimus therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — add-on sirolimus therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for add-on sirolimus therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ruijin Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRuijin Hospital

Related News